CL2017003475A1 - Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona - Google Patents

Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Info

Publication number
CL2017003475A1
CL2017003475A1 CL2017003475A CL2017003475A CL2017003475A1 CL 2017003475 A1 CL2017003475 A1 CL 2017003475A1 CL 2017003475 A CL2017003475 A CL 2017003475A CL 2017003475 A CL2017003475 A CL 2017003475A CL 2017003475 A1 CL2017003475 A1 CL 2017003475A1
Authority
CL
Chile
Prior art keywords
azetidin
piperidin
difluoro
fluoro
fumarate salt
Prior art date
Application number
CL2017003475A
Other languages
English (en)
Inventor
Adrian St Clair Brown
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CL2017003475A1 publication Critical patent/CL2017003475A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

<p>LA PRESENTE DESCRIPCIÓN SE REFIERE A LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3- HIDROXI-3-(PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA. LA DESCRIPCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3-(PIPERIDIN-2-IL) AZETIDIN-1-IL]-METANONA. LA DESCRIPCIÓN TAMBIÉN SE REFIERE A MÉTODOS PARA TRATAR CÁNCERES QUE COMPRENDEN ADMINISTRARLE A UN PACIENTE QUE LO NECESITA LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3- (PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA.</p>
CL2017003475A 2015-06-30 2017-12-29 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona CL2017003475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562187009P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
CL2017003475A1 true CL2017003475A1 (es) 2018-07-13

Family

ID=56411938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003475A CL2017003475A1 (es) 2015-06-30 2017-12-29 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Country Status (24)

Country Link
US (3) US10590102B2 (es)
EP (1) EP3317264A1 (es)
JP (3) JP7338950B2 (es)
KR (1) KR20180021775A (es)
CN (1) CN107810183A (es)
AR (1) AR105483A1 (es)
AU (2) AU2016288209B2 (es)
CA (1) CA2990222C (es)
CL (1) CL2017003475A1 (es)
CO (1) CO2018000086A2 (es)
CR (1) CR20180056A (es)
HK (1) HK1252433A1 (es)
IL (2) IL295052A (es)
MA (1) MA42301A (es)
MX (1) MX2017017037A (es)
MY (1) MY192545A (es)
PE (1) PE20180692A1 (es)
PH (1) PH12017502414A1 (es)
RU (2) RU2021132394A (es)
SG (1) SG10202105196YA (es)
TW (2) TWI710556B (es)
UA (1) UA124728C2 (es)
WO (1) WO2017004393A1 (es)
ZA (1) ZA201708760B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
HRP20240045T1 (hr) * 2015-06-30 2024-03-29 Genentech, Inc. Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
GB201717809D0 (en) * 2017-10-30 2017-12-13 Azad Pharmaceutical Ingredients Ag Process for the production of cobimetinib
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
SG11201507477XA (en) 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
JP2018519318A (ja) 2018-07-19
TWI710556B (zh) 2020-11-21
CA2990222C (en) 2023-09-26
KR20180021775A (ko) 2018-03-05
AU2021200202B2 (en) 2022-09-08
IL295052A (en) 2022-09-01
MA42301A (fr) 2018-05-09
IL256423B (en) 2022-09-01
PE20180692A1 (es) 2018-04-23
US10590102B2 (en) 2020-03-17
EP3317264A1 (en) 2018-05-09
CA2990222A1 (en) 2017-01-05
AU2016288209A1 (en) 2018-02-08
AU2021200202A1 (en) 2021-03-18
RU2018103172A (ru) 2019-07-31
HK1252433A1 (zh) 2019-05-24
JP7338950B2 (ja) 2023-09-05
TWI775187B (zh) 2022-08-21
US20220056010A1 (en) 2022-02-24
TW202108568A (zh) 2021-03-01
WO2017004393A1 (en) 2017-01-05
RU2021132394A (ru) 2021-11-18
US20200255398A1 (en) 2020-08-13
JP2021035967A (ja) 2021-03-04
CR20180056A (es) 2018-05-25
PH12017502414A1 (en) 2018-06-25
AR105483A1 (es) 2017-10-11
UA124728C2 (uk) 2021-11-10
US20180346442A1 (en) 2018-12-06
AU2016288209B2 (en) 2020-10-22
IL256423A (en) 2018-02-28
JP2023025000A (ja) 2023-02-21
SG10202105196YA (en) 2021-06-29
RU2762181C2 (ru) 2021-12-16
MY192545A (en) 2022-08-26
BR112017028516A2 (pt) 2018-08-28
CO2018000086A2 (es) 2018-04-10
TW201718535A (zh) 2017-06-01
US11254649B2 (en) 2022-02-22
RU2018103172A3 (es) 2019-10-31
CN107810183A (zh) 2018-03-16
ZA201708760B (en) 2022-06-29
MX2017017037A (es) 2018-04-30

Similar Documents

Publication Publication Date Title
CL2017003475A1 (es) Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2017001620A (es) Formas cristalinas de inhibidores de glutaminasa.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
JOP20200030A1 (ar) مركب خماسي الحلقة
PH12019500822A1 (en) Crystalline forms of eravacycline
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CY1122334T1 (el) Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης
CL2016003155A1 (es) Composiciones de cuidado bucal
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
SG10201810263QA (en) Nampt inhibitors and methods